Clinical Trial Finder

Inclusion Criteria.To participate in this study a participant must meet the eligibility of one of the following cohorts: Cohort 1: Cancers beginning initial treatment.

• - One of the following diagnoses: - Cohort 1A (CLOSED): ---Advanced non-squamous NSCLC (including adenosquamous) - Cohort 1B: - Stage II-III non-squamous NSCLC (including adenosquamous) - Stage IIIB-IV melanoma.

• - Patient must be planned to begin initial therapy, or completely resected before or after receiving adjuvant therapy.

• - For patients with NSCLC, EGFR and KRAS genotype may be known or unknown.

• - For patients with melanoma, BRAF and NRAS genotype may be known or unknown.

• - For patients without tumor genotyping, there must be a plan for genotyping including either: - Archived tumor tissue available and planned for genotyping.

• - A biopsy at some future time is anticipated and will be available for genotyping.

Cohort 2: Cancers with acquired resistance to targeted therapy.

• - One of the following diagnoses: - Cohort 2A (CLOSED): ---Advanced NSCLC harboring a known EGFR mutation.

• - Cohort 2B: - Advanced NSCLC harboring a targetable genotype other than EGFR.

• - Advanced melanoma harboring a known tumor genotype.

• - Clinical determination of progression targeted therapy, as evidence by plans to start a new systemic treatment regimen, or obtain a biopsy to plan a new treatment regimen.

• - New systemic treatment regimen planned OR.

• - Re-biopsy for resistance genotyping planned.

• - Note, date of targeted therapy start and clinical progression must be provided.

Cohort 3: Cancers with a known genotype starting palliative systemic therapy.Cohort 3A (CLOSED):

• - Advanced NSCLC harboring one of the following mutations: - EGFR exon 19 deletion.

• - EGFR L858R.

• - EGFR T790M.

• - KRAS G12X.

• - BRAF V600E.

• - Patients must be initiating palliative systemic therapy, either on or off a clinical trial.

Cohort 4: Paired plasma NGS and ddPCR.

• - Cohort 4A (CLOSED): - Advanced NSCLC, newly diagnosed or with progression following treatment.

• - Biopsy tissue must be available or a biopsy planned and one of the following: - Genotyping must have been performed previously.

• - Genotyping must be in progress.

• - A plan must exist to order genotyping on existing tissue or a planned re-biopsy.

• - Patient must not be eligible to enroll in cohort 1A or 2A due to: - Not eligible for cohort 1A or 2A.

• - Eligible for cohort 1A or 2A but cohort has closed.

• - Cohort 4B: Undergenotyped NSCLC.

• - Advanced NSCLC, newly diagnosed or with progression following treatment.

• - No known targetable genotype on prior tumor genotyping.

• - Biopsy planned for tumor genotyping.

• - Cohort 4C: EGFR-mutant NSCLC with acquired resistance.

• - Advanced EGFR-mutant NSCLC with progression on EGFR TKI.

• - Biopsy planned for resistance genotyping (e.g. T790M, etc) Cohort 5: Genotyped KRAS patients starting palliative systemic therapy.

• - Advanced NSCLC harboring a KRAS exon 2 mutation.

• - Patients must be initiating new systemic therapy, either on or off a clinical trial.

Exclusion Criteria.

• - Participants who are unable to provide informed consent.

• - Participants who are 18 years of age or younger.

- Participants who are unable to comply with the study procedures

Arms

: Newly Diagnosed Patients

Newly diagnosed patients with advanced NSCLC or melanoma with complete or planned tissue genotyping.

: Acquired Resistance Patients

NSCLC patients with a known EGFR mutation or other targetable mutation and acquired resistance to initial kinase inhibitor therapy.

: Known Genotype Patients

NSCLC patients with a known genomic alteration detectable by ddPCR-based plasma genotyping and planned to start a new line of therapy.

: Advanced NSCLC

Advanced NSCLC patients with a biopsy planned for tissue genotyping.

Interventions